A novel PPARγ agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways

Biochemical and Biophysical Research Communications

Volumn 378, Issue 3, 2009, Pages 645-649

  Park, Ju Young ^a,b   Bae, Myung Ae ^c   Cheon, Hyae Gyeong ^c   Kim, Sung Soo ^c   Hong, Jung Min ^a   Kim, Tae Ho ^a   Choi, Je Yong ^a,b   Kim, Sang Hyun ^b   Lim, Jiwon ^d   Choi, Chang Hyuk ^e   Shin, Hong In ^d   Kim, Shin Yoon ^a,b   Park, Eui Kyun ^a,d  

^a Kyungpook National University Hospital   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Korea Research Institute of Chemical Technology   (South Korea)

^d IHBR   (South Korea)

^e Catholic University of Daegu   (South Korea)

Author keywords

Bone resorption; Osteoclast differentiation; PPAR agonist

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; DENDRITIC CELL SPECIFIC TRANSMEMBRANE PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KR 62772; KR 62776; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROTEIN OSTEOCLAST ASSOCIATED RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; INDAN DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; OXIME; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CALVARIA; CELL DIFFERENTIATION; CELL FUNCTION; GENE CONTROL; GENE EXPRESSION; MOUSE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; ANIMAL; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYMOLOGY; GENETICS; INSTITUTE FOR CANCER RESEARCH MOUSE; OSTEOLYSIS; PHOSPHORYLATION;

ANIMALS; BONE RESORPTION; CELL DIFFERENTIATION; CELLS, CULTURED; GENE EXPRESSION; INDANS; MICE; MICE, INBRED ICR; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; OSTEOCLASTS; OXIMES; PHOSPHORYLATION; PPAR GAMMA; RANK LIGAND;

EID: 57749185888     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.11.115     Document Type: Article

References (23)

1. Darnay B.G., Haridas V., Ni J., Moore P.A., and Aggarwal B.B. Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. J. Biol. Chem. 273 (1998) 20551-20555
2. Lee S.E., Woo K.M., Kim S.Y., Kim H.M., Kwack K., Lee Z.H., and Kim H.H. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone 30 (2002) 71-77
3. Okazaki R., Toriumi M., Fukumoto S., Miyamoto M., Fujita T., Tanaka K., and Takeuchi Y. Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 140 (1999) 5060-5065
4. Sottile V., Seuwen K., and Kneissel M. Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (Rosiglitazone). Calcif. Tissue Int. 75 (2004) 329-337
5. Mbalaviele G., Abu-Amer Y., Meng A., Jaiswal R., Beck S., Pittenger M.F., Thiede M.A., and Marshak D.R. Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation. J. Biol. Chem. 275 (2000) 14388-14393
6. Ahn J.H., Shin M.S., Jung S.H., Kang S.K., Kim K.R., Rhee S.D., Jung W.H., Yang S.D., Kim S.J., Woo J.R., Lee J.H., Cheon H.G., and Kim S.S. Indenone derivatives: a novel template for peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. J. Med. Chem. 49 (2006) 4781-4784
7. Park E.K., Kim M.S., Lee S.H., Kim K.H., Park J.Y., Kim T.H., Lee I.S., Woo J.T., Jung J.C., Shin H.I., Choi J.Y., and Kim S.Y. Furosin, an ellagitannin, suppresses RANKL-induced osteoclast differentiation and function through inhibition of MAP kinase activation and actin ring formation. Biochem. Biophys. Res. Commun. 325 (2004) 1472-1480
8. Faccio R., Takeshita S., Zallone A., Ross F.P., and Teitelbaum S.L. C-Fms and the alphavbeta3 integrin collaborate during osteoclast differentiation. J. Clin. Invest. 111 (2003) 749-758
9. Battaglino R., Kim D., Fu J., Vaage B., Fu X.Y., and Stashenko P. C-myc is required for osteoclast differentiation. J. Bone Miner. Res. 17 (2002) 763-773
10. Sakiyama H., Masuda R., Inoue N., Yamamoto K., Kuriiwa K., Nakagawa K., and Yoshida K. Establishment and characterization of macrophage-like cell lines expressing osteoclast-specific markers. J. Bone Miner. Metab. 19 (2001) 220-227
11. Xing L., Bushnell T.P., Carlson L., Tai Z., Tondravi M., Siebenlist U., Young F., and Boyce B.F. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J. Bone Miner. Res. 17 (2002) 1200-1210
12. Clark R.B., Bishop-Bailey D., Estrada-Hernandez T., Hla T., Puddington L., and Padula S.J. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J. Immunol. 164 (2000) 1364-1371
13. Miyamoto T., Ohneda O., Arai F., Iwamoto K., Okada S., Takagi K., Anderson D.M., and Suda T. Bifurcation of osteoclasts and dendritic cells from common progenitors. Blood 98 (2001) 2544-2554
14. Vukosavic S., Stefanis L., Jackson-Lewis V., Guegan C., Romero N., Chen C., Dubois-Dauphin M., and Przedborski S. Delaying caspase activation by Bcl-2: A clue to disease retardation in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci. 20 (2000) 9119-9125
15. Wan Y., Chong L.W., and Evans R.M. PPAR-gamma regulates osteoclastogenesis in mice. Nat. Med. 13 (2007) 1496-1503
16. Hayashi S., Yamada T., Tsuneto M., Yamane T., Takahashi M., Shultz L.D., and Yamazaki H. Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha. J. Immunol. 171 (2003) 5130-5139
17. Lazarenko O.P., Rzonca S.O., Hogue W.R., Swain F.L., Suva L.J., and Lecka-Czernik B. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148 (2007) 2669-2680
18. Tomita T., Kakiuchi Y., and Tsao P.S. THR0921, a novel peroxisome proliferator-activated receptor gamma agonist, reduces the severity of collagen-induced arthritis. Arthritis Res. Ther. 8 (2006) R7
19. Lowe C., Yoneda T., Boyce B.F., Chen H., Mundy G.R., and Soriano P. Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc. Natl. Acad. Sci. USA 90 (1993) 4485-4489
20. McHugh K.P., Hodivala-Dilke K., Zheng M.H., Namba N., Lam J., Novack D., Feng X., Ross F.P., Hynes R.O., and Teitelbaum S.L. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J. Clin. Invest. 105 (2000) 433-440
21. Boyle W.J., Simonet W.S., and Lacey D.L. Osteoclast differentiation and activation. Nature 423 (2003) 337-342
22. Rodriguez-Calvo R., Serrano L., Coll T., Moullan N., Sanchez R.M., Merlos M., Palomer X., Laguna J.C., Michalik L., Wahli W., and Vazquez-Carrera M. Activation of peroxisome proliferator-activated receptor beta/delta inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signal-related kinase 1/2. Diabetes 57 (2008) 2149-2157
23. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79-82